AU2003264514A8 - Wt1 substitution peptides - Google Patents

Wt1 substitution peptides

Info

Publication number
AU2003264514A8
AU2003264514A8 AU2003264514A AU2003264514A AU2003264514A8 AU 2003264514 A8 AU2003264514 A8 AU 2003264514A8 AU 2003264514 A AU2003264514 A AU 2003264514A AU 2003264514 A AU2003264514 A AU 2003264514A AU 2003264514 A8 AU2003264514 A8 AU 2003264514A8
Authority
AU
Australia
Prior art keywords
peptides
asn
polynucleotides
leu
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003264514A
Other versions
AU2003264514A1 (en
Inventor
Naoto Kusunose
Masashi Nakatsuka
Haruo Sugiyama
Masashi Gotoh
Hideo Takasu
Fumio Samizo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Chugai Pharmaceutical Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Chugai Pharmaceutical Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2003264514A8 publication Critical patent/AU2003264514A8/en
Publication of AU2003264514A1 publication Critical patent/AU2003264514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Seasonings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. <??>Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.
AU2003264514A 2002-09-20 2003-09-19 Wt1 substitution peptides Abandoned AU2003264514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002275264 2002-09-20
JP2002-275264 2002-09-20
PCT/JP2003/011974 WO2004026897A1 (en) 2002-09-20 2003-09-19 Wt1 substitution peptides

Publications (2)

Publication Number Publication Date
AU2003264514A8 true AU2003264514A8 (en) 2004-04-08
AU2003264514A1 AU2003264514A1 (en) 2004-04-08

Family

ID=32025026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003264514A Abandoned AU2003264514A1 (en) 2002-09-20 2003-09-19 Wt1 substitution peptides

Country Status (8)

Country Link
US (1) US7378384B2 (en)
EP (1) EP1548028B1 (en)
JP (1) JP4480580B2 (en)
AT (1) ATE442378T1 (en)
AU (1) AU2003264514A1 (en)
DE (1) DE60329201D1 (en)
ES (1) ES2331305T3 (en)
WO (1) WO2004026897A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006602A1 (en) * 1998-07-31 2000-02-10 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
BRPI0208183B8 (en) * 2001-03-22 2021-05-25 Sugiyama Haruo wt1 modified cancer antigen peptide and cancer vaccines
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
CN100513563C (en) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1-origin HLA-DR-binding antigen peptide
WO2005095598A1 (en) * 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide originating in wt1
WO2005116056A1 (en) * 2004-05-26 2005-12-08 Green Peptide Co., Ltd. Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
AU2006319892B2 (en) * 2005-11-30 2012-05-10 International Institute Of Cancer Immunology, Inc. Novel peptide compound
AU2008220031B2 (en) 2007-02-27 2013-06-13 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
US9117133B2 (en) * 2008-06-18 2015-08-25 Spectral Image, Inc. Systems and methods for hyperspectral imaging
AT508569A1 (en) 2009-07-23 2011-02-15 Affiris Ag PHARMACEUTICAL COMPOUND
AU2011313327B2 (en) 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
CN106632677B (en) * 2011-04-01 2021-10-26 纪念斯隆-凯特琳癌症中心 T cell receptor-like antibodies specific for WT1peptide presented by HLA-A2
WO2014007266A1 (en) 2012-07-02 2014-01-09 大日本住友製薬株式会社 Transdermal cancer antigen peptide preparation
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
RU2687144C2 (en) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Anticancer vaccine composition containing wt1 peptide for transdermal administration
CN103961699B (en) 2013-02-05 2018-11-06 日东电工株式会社 For percutaneous administration of with WT1 peptide cancer vaccine compositions
RU2687026C2 (en) 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Vaccine composition against malignant tumor based on peptide wt1 for mucosal introduction
KR102050931B1 (en) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 Tape preparation of wt1 peptide cancer vaccine for transdermal administration
WO2014142102A1 (en) 2013-03-12 2014-09-18 大日本住友製薬株式会社 Liquid aqueous composition
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20160310584A1 (en) * 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
WO2018101309A1 (en) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Wt1 helper peptide, and combination of said peptide and cancer antigen peptide conjugate
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018181648A1 (en) 2017-03-30 2018-10-04 大日本住友製薬株式会社 Wt1 cancer antigen peptide and peptide conjugate body containing same
MX2021003660A (en) 2018-09-28 2021-05-28 Sumitomo Pharma Co Ltd Injectable composition.
CA3115240A1 (en) 2018-10-05 2020-04-09 International Institute Of Cancer Immunology, Inc. Composition for preventing or treating benign tumor
TW202045528A (en) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 Method for selecting subject likely benefiting from pharmaceutical composition for treating or preventing cancer
KR20230009426A (en) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 Pharmaceutical composition for treating cancer
JPWO2023017836A1 (en) 2021-08-12 2023-02-16

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006602A1 (en) 1998-07-31 2000-02-10 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
IL142216A0 (en) * 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
BRPI0208183B8 (en) 2001-03-22 2021-05-25 Sugiyama Haruo wt1 modified cancer antigen peptide and cancer vaccines
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells

Also Published As

Publication number Publication date
EP1548028A1 (en) 2005-06-29
DE60329201D1 (en) 2009-10-22
EP1548028B1 (en) 2009-09-09
EP1548028A4 (en) 2006-03-15
ES2331305T3 (en) 2009-12-29
JP4480580B2 (en) 2010-06-16
WO2004026897A1 (en) 2004-04-01
US20060205667A1 (en) 2006-09-14
ATE442378T1 (en) 2009-09-15
JPWO2004026897A1 (en) 2006-01-19
US7378384B2 (en) 2008-05-27
AU2003264514A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2003264514A8 (en) Wt1 substitution peptides
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
HK1119955A1 (en) Modified kunitz domain polypeptide
US6080398A (en) Truncated gro and KC chemokines having enhanced bioactivity
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
IL154575A (en) Cyclic peptides , process for their preparation and uses thereof in the preparation of a medicament for the treatment of diseases associated with mc4-r activity
DE69942035D1 (en) HUMAN PARATHYROIDHORMONE, MODIFICATIONS, MANUFACTURE AND USE
AR006517A1 (en) POLYPEPTIDE THAT REACHES A TOTAL AROUND 30 AMINO ACIDS; RESULTANT SUBSTANCE, PEPTIDOMIMETICO AND PHARMACEUTICAL COMPOSITION; USES OF THE POLYPEPTIDE AND PROCESS FOR THE SYNTHESIS OF THE POLYPEPTIDE.
CA2097192A1 (en) Bombesin antagonists
AU2002330289A1 (en) Preparation of a therapeutic composition
IE65533B1 (en) Hemoregulatory peptides
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
AU3440293A (en) Hemoregulatory peptides
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
EP0258203A3 (en) Novel substrate peptides
EP1908781A3 (en) Modulation of immune response and methods based thereon
JP2004505616A5 (en)
KR102166543B1 (en) Composition and Method for Inhibiting Keloid
WO2004074312A3 (en) Tryptophyllin peptides and uses thereof
US5776900A (en) Hemoregulatory peptides
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
ATE305478T1 (en) TOPOISOMERASE-II INHIBITORS
Yang et al. Design and synthesis of salmon calcitonin analogs
CY1115911T1 (en) MODIFIED KUNITZ AREA POLYPTIPES AND USE IN REDUCING ISCHEMIA OR STARTING A SYSTEMATIC INFECTION INFECTION
AU2002238532A1 (en) Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase